^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:TheraMap Test
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Intermountain HealthcareType:
Laboratory Developed Test
TheraMap is a hybrid capture DNA- and RNA-based test that detects SNV, INDELs, Copy Number Variants (CNV), and fusions in solid tumors. TheraMap is validated for all solid tumor types and includes sequencing over 500 genes identified as relevant to cancer treatment, relevant gene fusion events, including NTRK fusions, as well as the important microsatellite instability (MSI) and tumor mutational burden (TMB) biomarkers.
Cancer:
Solid Tumor
Gene:
ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase), AKT1 (V-akt murine thymoma viral oncogene homolog 1), ARAF (A-Raf Proto-Oncogene), ARID2 (AT-Rich Interaction Domain 2), ASXL1 (ASXL Transcriptional Regulator 1), AURKA (Aurora kinase A)
See More ...
ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase), AKT1 (V-akt murine thymoma viral oncogene homolog 1), ARAF (A-Raf Proto-Oncogene), ARID2 (AT-Rich Interaction Domain 2), ASXL1 (ASXL Transcriptional Regulator 1), AURKA (Aurora kinase A), AURKB (Aurora Kinase B), AXIN1 (Axin 1), BAP1 (BRCA1 Associated Protein 1), BARD1 (BRCA1 Associated RING Domain 1), BCL2L1 (BCL2-like 1), BCL6 (B-cell CLL/lymphoma 6), BCOR (BCL6 Corepressor), BIRC3 (Baculoviral IAP repeat containing 3), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CARD11 (Caspase Recruitment Domain Family Member 11), CASP8 (Caspase 8), CBL (Cbl proto-oncogene), CCND2 (Cyclin D2), CD276 (CD276 Molecule), CD74 (CD74 Molecule), CD79B (CD79b Molecule), CDH1 (Cadherin 1), CDKN1A (Cyclin-dependent kinase inhibitor 1A), CDKN1B (Cyclin dependent kinase inhibitor 1B), CEBPA (CCAAT Enhancer Binding Protein Alpha), CENPA (Centromere protein A), CHD4 (Chromodomain Helicase DNA Binding Protein 4), CREBBP (CREB binding protein), CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), CXCR4 (Chemokine (C-X-C motif) receptor 4), DDR2 (Discoidin domain receptor 2), E2F3 (E2F transcription factor 3), EPCAM (Epithelial cell adhesion molecule), EPHA3 (EPH receptor A3), EPHA5 (EPH Receptor A5), ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit), ERCC5 (ERCC Excision Repair 5 Endonuclease 2), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), FANCA (FA Complementation Group A), FANCC (FA Complementation Group C), FOXA1 (Forkhead Box A1), MSI (Microsatellite instability), NOTCH4 (Notch 4), NTRK (Neurotrophic receptor tyrosine kinase), PD-L1 (Programmed death ligand 1), PTCH1 (Patched 1), RAD50 (RAD50 Double Strand Break Repair Protein), RAD51 (RAD51 Homolog A), SMAD2 (SMAD Family Member 2), SMAD3 (SMAD Family Member 3), SMAD4 (SMAD family member 4), STAT3 (Signal Transducer And Activator Of Transcription 3), STAT4 (Signal Transducer And Activator Of Transcription 4), STAT5B (Signal Transducer And Activator Of Transcription 5B), TERT (Telomerase Reverse Transcriptase), TET1 (Tet Methylcytosine Dioxygenase 1), TET2 (Tet Methylcytosine Dioxygenase 2), TMB (Tumor Mutational Burden), TOP2A (DNA topoisomerase 2-alpha), TP63 (Tumor protein 63), TSC1 (TSC complex subunit 1), TSC2 (TSC complex subunit 2), YAP1 (Yes associated protein 1)
Method:
Next-Generation Sequencing (NGS)
